As per the terms of the collaboration, Novozymes receives non-exclusive license to use MorphoSys’s Slonomics technology to develop novel products within the industrial biotechnology sector.
The Advanced Protein Engineering Technology will help Novozymes to bring down discovery time and expand project portfolio of their biological tools.
Slonomics technology, which is believed to comprise patented methods, advanced materials and robotic equipment, allows combination of building blocks of the biological reagent in exactly the preferred order and composition.
Financial details of the deal, however, have not been disclosed.